nodes	percent_of_prediction	percent_of_DWPC	metapath
Rivaroxaban—ABCB1—hematologic cancer	0.144	1	CbGaD
Rivaroxaban—ABCB1—Lenalidomide—hematologic cancer	0.0261	0.0494	CbGbCtD
Rivaroxaban—CYP3A5—Daunorubicin—hematologic cancer	0.0235	0.0445	CbGbCtD
Rivaroxaban—CYP3A5—Thalidomide—hematologic cancer	0.0214	0.0405	CbGbCtD
Rivaroxaban—CYP3A5—Teniposide—hematologic cancer	0.0204	0.0387	CbGbCtD
Rivaroxaban—CYP3A5—Ifosfamide—hematologic cancer	0.0189	0.0357	CbGbCtD
Rivaroxaban—CYP3A5—Imatinib—hematologic cancer	0.018	0.0341	CbGbCtD
Rivaroxaban—CYP3A4—Bexarotene—hematologic cancer	0.0156	0.0296	CbGbCtD
Rivaroxaban—ABCB1—Daunorubicin—hematologic cancer	0.0153	0.029	CbGbCtD
Rivaroxaban—ABCB1—Alitretinoin—hematologic cancer	0.015	0.0284	CbGbCtD
Rivaroxaban—CYP3A4—Busulfan—hematologic cancer	0.0145	0.0275	CbGbCtD
Rivaroxaban—CYP3A4—Lomustine—hematologic cancer	0.0145	0.0275	CbGbCtD
Rivaroxaban—CYP3A5—Dasatinib—hematologic cancer	0.0145	0.0274	CbGbCtD
Rivaroxaban—CYP3A4—Thiotepa—hematologic cancer	0.013	0.0245	CbGbCtD
Rivaroxaban—ABCB1—Imatinib—hematologic cancer	0.0117	0.0222	CbGbCtD
Rivaroxaban—CYP3A5—Irinotecan—hematologic cancer	0.0112	0.0213	CbGbCtD
Rivaroxaban—ABCB1—Nilotinib—hematologic cancer	0.0107	0.0202	CbGbCtD
Rivaroxaban—ABCB1—Vinorelbine—hematologic cancer	0.0106	0.02	CbGbCtD
Rivaroxaban—CYP3A4—Methoxsalen—hematologic cancer	0.0101	0.0191	CbGbCtD
Rivaroxaban—CYP3A5—Vincristine—hematologic cancer	0.00983	0.0186	CbGbCtD
Rivaroxaban—CYP3A4—Bortezomib—hematologic cancer	0.00958	0.0181	CbGbCtD
Rivaroxaban—ABCB1—Dasatinib—hematologic cancer	0.00941	0.0178	CbGbCtD
Rivaroxaban—ABCB1—Mitoxantrone—hematologic cancer	0.0093	0.0176	CbGbCtD
Rivaroxaban—CYP3A4—Daunorubicin—hematologic cancer	0.00917	0.0174	CbGbCtD
Rivaroxaban—CYP3A5—Etoposide—hematologic cancer	0.00901	0.0171	CbGbCtD
Rivaroxaban—ABCB1—Betamethasone—hematologic cancer	0.00829	0.0157	CbGbCtD
Rivaroxaban—ABCB1—Gemcitabine—hematologic cancer	0.00821	0.0156	CbGbCtD
Rivaroxaban—ABCB1—Prednisolone—hematologic cancer	0.00818	0.0155	CbGbCtD
Rivaroxaban—CYP3A4—Cytarabine—hematologic cancer	0.00809	0.0153	CbGbCtD
Rivaroxaban—CYP3A4—Teniposide—hematologic cancer	0.00796	0.0151	CbGbCtD
Rivaroxaban—ABCB1—Prednisone—hematologic cancer	0.00772	0.0146	CbGbCtD
Rivaroxaban—CYP3A5—Dexamethasone—hematologic cancer	0.00741	0.014	CbGbCtD
Rivaroxaban—CYP3A4—Ifosfamide—hematologic cancer	0.00735	0.0139	CbGbCtD
Rivaroxaban—ABCB1—Irinotecan—hematologic cancer	0.00732	0.0139	CbGbCtD
Rivaroxaban—CYP3A4—Imatinib—hematologic cancer	0.00702	0.0133	CbGbCtD
Rivaroxaban—CYP3A4—Ruxolitinib—hematologic cancer	0.00661	0.0125	CbGbCtD
Rivaroxaban—ABCB1—Vinblastine—hematologic cancer	0.00651	0.0123	CbGbCtD
Rivaroxaban—ABCB1—Vincristine—hematologic cancer	0.0064	0.0121	CbGbCtD
Rivaroxaban—CYP3A4—Nilotinib—hematologic cancer	0.00638	0.0121	CbGbCtD
Rivaroxaban—CYP3A4—Vinorelbine—hematologic cancer	0.00633	0.012	CbGbCtD
Rivaroxaban—ABCB1—Cisplatin—hematologic cancer	0.00597	0.0113	CbGbCtD
Rivaroxaban—ABCB1—Etoposide—hematologic cancer	0.00586	0.0111	CbGbCtD
Rivaroxaban—CYP3A4—Triamcinolone—hematologic cancer	0.00579	0.011	CbGbCtD
Rivaroxaban—CYP3A4—Dasatinib—hematologic cancer	0.00564	0.0107	CbGbCtD
Rivaroxaban—CYP3A4—Mitoxantrone—hematologic cancer	0.00557	0.0105	CbGbCtD
Rivaroxaban—CYP3A4—Betamethasone—hematologic cancer	0.00497	0.0094	CbGbCtD
Rivaroxaban—CYP3A4—Prednisolone—hematologic cancer	0.0049	0.00928	CbGbCtD
Rivaroxaban—ABCB1—Dexamethasone—hematologic cancer	0.00482	0.00913	CbGbCtD
Rivaroxaban—CYP3A4—Prednisone—hematologic cancer	0.00463	0.00876	CbGbCtD
Rivaroxaban—CYP3A4—Irinotecan—hematologic cancer	0.00439	0.0083	CbGbCtD
Rivaroxaban—ABCB1—Doxorubicin—hematologic cancer	0.004	0.00757	CbGbCtD
Rivaroxaban—CYP3A4—Vinblastine—hematologic cancer	0.0039	0.00738	CbGbCtD
Rivaroxaban—ABCB1—Methotrexate—hematologic cancer	0.00387	0.00734	CbGbCtD
Rivaroxaban—CYP3A4—Vincristine—hematologic cancer	0.00383	0.00726	CbGbCtD
Rivaroxaban—CYP3A4—Etoposide—hematologic cancer	0.00351	0.00665	CbGbCtD
Rivaroxaban—CYP3A4—Dexamethasone—hematologic cancer	0.00289	0.00547	CbGbCtD
Rivaroxaban—F10—hematopoietic system—hematologic cancer	0.00246	0.172	CbGeAlD
Rivaroxaban—CYP3A4—Doxorubicin—hematologic cancer	0.0024	0.00454	CbGbCtD
Rivaroxaban—F10—blood—hematologic cancer	0.00163	0.114	CbGeAlD
Rivaroxaban—F10—lung—hematologic cancer	0.00143	0.0997	CbGeAlD
Rivaroxaban—F10—testis—hematologic cancer	0.00135	0.0941	CbGeAlD
Rivaroxaban—CYP2J2—lung—hematologic cancer	0.00117	0.0817	CbGeAlD
Rivaroxaban—CYP2J2—testis—hematologic cancer	0.00111	0.0771	CbGeAlD
Rivaroxaban—F10—lymph node—hematologic cancer	0.000978	0.0682	CbGeAlD
Rivaroxaban—CYP3A5—hematopoietic system—hematologic cancer	0.00071	0.0495	CbGeAlD
Rivaroxaban—CYP3A4—hematopoietic system—hematologic cancer	0.000533	0.0372	CbGeAlD
Rivaroxaban—CYP3A5—blood—hematologic cancer	0.00047	0.0328	CbGeAlD
Rivaroxaban—CYP3A5—lung—hematologic cancer	0.000412	0.0288	CbGeAlD
Rivaroxaban—ABCB1—hematopoietic system—hematologic cancer	0.000377	0.0263	CbGeAlD
Rivaroxaban—CYP3A4—blood—hematologic cancer	0.000353	0.0246	CbGeAlD
Rivaroxaban—ABCB1—gonad—hematologic cancer	0.000287	0.02	CbGeAlD
Rivaroxaban—ABCB1—blood—hematologic cancer	0.00025	0.0174	CbGeAlD
Rivaroxaban—ABCB1—bone marrow—hematologic cancer	0.000242	0.0169	CbGeAlD
Rivaroxaban—ABCB1—lung—hematologic cancer	0.000219	0.0153	CbGeAlD
Rivaroxaban—ABCB1—testis—hematologic cancer	0.000207	0.0144	CbGeAlD
Rivaroxaban—ABCB1—lymph node—hematologic cancer	0.00015	0.0105	CbGeAlD
Rivaroxaban—Urethral disorder—Epirubicin—hematologic cancer	3.58e-05	0.000142	CcSEcCtD
Rivaroxaban—Headache—Vincristine—hematologic cancer	3.58e-05	0.000142	CcSEcCtD
Rivaroxaban—Loss of consciousness—Prednisone—hematologic cancer	3.58e-05	0.000142	CcSEcCtD
Rivaroxaban—Hepatobiliary disease—Doxorubicin—hematologic cancer	3.56e-05	0.000142	CcSEcCtD
Rivaroxaban—Hypotension—Betamethasone—hematologic cancer	3.56e-05	0.000142	CcSEcCtD
Rivaroxaban—Hypotension—Dexamethasone—hematologic cancer	3.56e-05	0.000142	CcSEcCtD
Rivaroxaban—Nausea—Carmustine—hematologic cancer	3.56e-05	0.000142	CcSEcCtD
Rivaroxaban—Epistaxis—Doxorubicin—hematologic cancer	3.55e-05	0.000141	CcSEcCtD
Rivaroxaban—Angiopathy—Methotrexate—hematologic cancer	3.54e-05	0.000141	CcSEcCtD
Rivaroxaban—Vomiting—Irinotecan—hematologic cancer	3.54e-05	0.000141	CcSEcCtD
Rivaroxaban—Vomiting—Mitoxantrone—hematologic cancer	3.54e-05	0.000141	CcSEcCtD
Rivaroxaban—Sinusitis—Doxorubicin—hematologic cancer	3.53e-05	0.000141	CcSEcCtD
Rivaroxaban—Immune system disorder—Methotrexate—hematologic cancer	3.53e-05	0.00014	CcSEcCtD
Rivaroxaban—Nausea—Alitretinoin—hematologic cancer	3.52e-05	0.00014	CcSEcCtD
Rivaroxaban—Mediastinal disorder—Methotrexate—hematologic cancer	3.52e-05	0.00014	CcSEcCtD
Rivaroxaban—Agranulocytosis—Doxorubicin—hematologic cancer	3.52e-05	0.00014	CcSEcCtD
Rivaroxaban—Rash—Mitoxantrone—hematologic cancer	3.51e-05	0.00014	CcSEcCtD
Rivaroxaban—Rash—Irinotecan—hematologic cancer	3.51e-05	0.00014	CcSEcCtD
Rivaroxaban—Dermatitis—Mitoxantrone—hematologic cancer	3.51e-05	0.00014	CcSEcCtD
Rivaroxaban—Dermatitis—Irinotecan—hematologic cancer	3.51e-05	0.00014	CcSEcCtD
Rivaroxaban—Headache—Irinotecan—hematologic cancer	3.49e-05	0.000139	CcSEcCtD
Rivaroxaban—Headache—Mitoxantrone—hematologic cancer	3.49e-05	0.000139	CcSEcCtD
Rivaroxaban—Nausea—Ifosfamide—hematologic cancer	3.48e-05	0.000139	CcSEcCtD
Rivaroxaban—Feeling abnormal—Triamcinolone—hematologic cancer	3.46e-05	0.000138	CcSEcCtD
Rivaroxaban—Diarrhoea—Cisplatin—hematologic cancer	3.46e-05	0.000138	CcSEcCtD
Rivaroxaban—Erythema multiforme—Epirubicin—hematologic cancer	3.46e-05	0.000137	CcSEcCtD
Rivaroxaban—Vomiting—Gemcitabine—hematologic cancer	3.45e-05	0.000137	CcSEcCtD
Rivaroxaban—Unspecified disorder of skin and subcutaneous tissue—Prednisone—hematologic cancer	3.44e-05	0.000137	CcSEcCtD
Rivaroxaban—Discomfort—Prednisone—hematologic cancer	3.42e-05	0.000136	CcSEcCtD
Rivaroxaban—Rash—Gemcitabine—hematologic cancer	3.42e-05	0.000136	CcSEcCtD
Rivaroxaban—Dermatitis—Gemcitabine—hematologic cancer	3.42e-05	0.000136	CcSEcCtD
Rivaroxaban—Eye disorder—Epirubicin—hematologic cancer	3.42e-05	0.000136	CcSEcCtD
Rivaroxaban—Hypersensitivity—Etoposide—hematologic cancer	3.41e-05	0.000136	CcSEcCtD
Rivaroxaban—Haemoglobin—Doxorubicin—hematologic cancer	3.4e-05	0.000135	CcSEcCtD
Rivaroxaban—Headache—Gemcitabine—hematologic cancer	3.4e-05	0.000135	CcSEcCtD
Rivaroxaban—Nausea—Vincristine—hematologic cancer	3.4e-05	0.000135	CcSEcCtD
Rivaroxaban—Cardiac disorder—Epirubicin—hematologic cancer	3.39e-05	0.000135	CcSEcCtD
Rivaroxaban—Haemorrhage—Doxorubicin—hematologic cancer	3.38e-05	0.000134	CcSEcCtD
Rivaroxaban—Hepatitis—Doxorubicin—hematologic cancer	3.38e-05	0.000134	CcSEcCtD
Rivaroxaban—Hypersensitivity—Prednisolone—hematologic cancer	3.37e-05	0.000134	CcSEcCtD
Rivaroxaban—Dyspepsia—Dexamethasone—hematologic cancer	3.36e-05	0.000133	CcSEcCtD
Rivaroxaban—Dyspepsia—Betamethasone—hematologic cancer	3.36e-05	0.000133	CcSEcCtD
Rivaroxaban—Urinary tract disorder—Doxorubicin—hematologic cancer	3.34e-05	0.000133	CcSEcCtD
Rivaroxaban—Urticaria—Triamcinolone—hematologic cancer	3.34e-05	0.000133	CcSEcCtD
Rivaroxaban—Asthenia—Etoposide—hematologic cancer	3.32e-05	0.000132	CcSEcCtD
Rivaroxaban—Connective tissue disorder—Doxorubicin—hematologic cancer	3.32e-05	0.000132	CcSEcCtD
Rivaroxaban—Oedema—Prednisone—hematologic cancer	3.32e-05	0.000132	CcSEcCtD
Rivaroxaban—Anaphylactic shock—Prednisone—hematologic cancer	3.32e-05	0.000132	CcSEcCtD
Rivaroxaban—Angiopathy—Epirubicin—hematologic cancer	3.32e-05	0.000132	CcSEcCtD
Rivaroxaban—Urethral disorder—Doxorubicin—hematologic cancer	3.31e-05	0.000132	CcSEcCtD
Rivaroxaban—Nausea—Mitoxantrone—hematologic cancer	3.31e-05	0.000132	CcSEcCtD
Rivaroxaban—Nausea—Irinotecan—hematologic cancer	3.31e-05	0.000132	CcSEcCtD
Rivaroxaban—Immune system disorder—Epirubicin—hematologic cancer	3.3e-05	0.000131	CcSEcCtD
Rivaroxaban—Infection—Prednisone—hematologic cancer	3.3e-05	0.000131	CcSEcCtD
Rivaroxaban—Mediastinal disorder—Epirubicin—hematologic cancer	3.29e-05	0.000131	CcSEcCtD
Rivaroxaban—Gastrointestinal disorder—Betamethasone—hematologic cancer	3.29e-05	0.000131	CcSEcCtD
Rivaroxaban—Gastrointestinal disorder—Dexamethasone—hematologic cancer	3.29e-05	0.000131	CcSEcCtD
Rivaroxaban—Back pain—Methotrexate—hematologic cancer	3.29e-05	0.000131	CcSEcCtD
Rivaroxaban—Fatigue—Betamethasone—hematologic cancer	3.29e-05	0.000131	CcSEcCtD
Rivaroxaban—Fatigue—Dexamethasone—hematologic cancer	3.29e-05	0.000131	CcSEcCtD
Rivaroxaban—Pruritus—Etoposide—hematologic cancer	3.28e-05	0.00013	CcSEcCtD
Rivaroxaban—Shock—Prednisone—hematologic cancer	3.27e-05	0.00013	CcSEcCtD
Rivaroxaban—Pain—Betamethasone—hematologic cancer	3.26e-05	0.00013	CcSEcCtD
Rivaroxaban—Pain—Dexamethasone—hematologic cancer	3.26e-05	0.00013	CcSEcCtD
Rivaroxaban—Nervous system disorder—Prednisone—hematologic cancer	3.26e-05	0.000129	CcSEcCtD
Rivaroxaban—Tachycardia—Prednisone—hematologic cancer	3.24e-05	0.000129	CcSEcCtD
Rivaroxaban—Skin disorder—Prednisone—hematologic cancer	3.22e-05	0.000128	CcSEcCtD
Rivaroxaban—Nausea—Gemcitabine—hematologic cancer	3.22e-05	0.000128	CcSEcCtD
Rivaroxaban—Vomiting—Cisplatin—hematologic cancer	3.21e-05	0.000128	CcSEcCtD
Rivaroxaban—Erythema multiforme—Doxorubicin—hematologic cancer	3.2e-05	0.000127	CcSEcCtD
Rivaroxaban—Rash—Cisplatin—hematologic cancer	3.19e-05	0.000127	CcSEcCtD
Rivaroxaban—Dermatitis—Cisplatin—hematologic cancer	3.19e-05	0.000127	CcSEcCtD
Rivaroxaban—Diarrhoea—Etoposide—hematologic cancer	3.17e-05	0.000126	CcSEcCtD
Rivaroxaban—Eye disorder—Doxorubicin—hematologic cancer	3.16e-05	0.000126	CcSEcCtD
Rivaroxaban—Ill-defined disorder—Methotrexate—hematologic cancer	3.15e-05	0.000125	CcSEcCtD
Rivaroxaban—Anaemia—Methotrexate—hematologic cancer	3.14e-05	0.000125	CcSEcCtD
Rivaroxaban—Feeling abnormal—Dexamethasone—hematologic cancer	3.14e-05	0.000125	CcSEcCtD
Rivaroxaban—Feeling abnormal—Betamethasone—hematologic cancer	3.14e-05	0.000125	CcSEcCtD
Rivaroxaban—Cardiac disorder—Doxorubicin—hematologic cancer	3.14e-05	0.000125	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Betamethasone—hematologic cancer	3.12e-05	0.000124	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Dexamethasone—hematologic cancer	3.12e-05	0.000124	CcSEcCtD
Rivaroxaban—Hypersensitivity—Triamcinolone—hematologic cancer	3.1e-05	0.000123	CcSEcCtD
Rivaroxaban—Back pain—Epirubicin—hematologic cancer	3.08e-05	0.000122	CcSEcCtD
Rivaroxaban—Angiopathy—Doxorubicin—hematologic cancer	3.07e-05	0.000122	CcSEcCtD
Rivaroxaban—Malaise—Methotrexate—hematologic cancer	3.07e-05	0.000122	CcSEcCtD
Rivaroxaban—Dizziness—Etoposide—hematologic cancer	3.06e-05	0.000122	CcSEcCtD
Rivaroxaban—Muscle spasms—Epirubicin—hematologic cancer	3.06e-05	0.000122	CcSEcCtD
Rivaroxaban—Immune system disorder—Doxorubicin—hematologic cancer	3.05e-05	0.000121	CcSEcCtD
Rivaroxaban—Mediastinal disorder—Doxorubicin—hematologic cancer	3.05e-05	0.000121	CcSEcCtD
Rivaroxaban—Urticaria—Dexamethasone—hematologic cancer	3.03e-05	0.00012	CcSEcCtD
Rivaroxaban—Urticaria—Betamethasone—hematologic cancer	3.03e-05	0.00012	CcSEcCtD
Rivaroxaban—Dizziness—Prednisolone—hematologic cancer	3.02e-05	0.00012	CcSEcCtD
Rivaroxaban—Asthenia—Triamcinolone—hematologic cancer	3.01e-05	0.00012	CcSEcCtD
Rivaroxaban—Abdominal pain—Dexamethasone—hematologic cancer	3.01e-05	0.00012	CcSEcCtD
Rivaroxaban—Abdominal pain—Betamethasone—hematologic cancer	3.01e-05	0.00012	CcSEcCtD
Rivaroxaban—Nausea—Cisplatin—hematologic cancer	3e-05	0.000119	CcSEcCtD
Rivaroxaban—Pruritus—Triamcinolone—hematologic cancer	2.97e-05	0.000118	CcSEcCtD
Rivaroxaban—Ill-defined disorder—Epirubicin—hematologic cancer	2.95e-05	0.000117	CcSEcCtD
Rivaroxaban—Vomiting—Etoposide—hematologic cancer	2.95e-05	0.000117	CcSEcCtD
Rivaroxaban—Anaemia—Epirubicin—hematologic cancer	2.94e-05	0.000117	CcSEcCtD
Rivaroxaban—Dyspepsia—Prednisone—hematologic cancer	2.92e-05	0.000116	CcSEcCtD
Rivaroxaban—Rash—Etoposide—hematologic cancer	2.92e-05	0.000116	CcSEcCtD
Rivaroxaban—Dermatitis—Etoposide—hematologic cancer	2.92e-05	0.000116	CcSEcCtD
Rivaroxaban—Headache—Etoposide—hematologic cancer	2.9e-05	0.000115	CcSEcCtD
Rivaroxaban—Chest pain—Methotrexate—hematologic cancer	2.89e-05	0.000115	CcSEcCtD
Rivaroxaban—Rash—Prednisolone—hematologic cancer	2.88e-05	0.000115	CcSEcCtD
Rivaroxaban—Dermatitis—Prednisolone—hematologic cancer	2.88e-05	0.000114	CcSEcCtD
Rivaroxaban—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	2.87e-05	0.000114	CcSEcCtD
Rivaroxaban—Malaise—Epirubicin—hematologic cancer	2.87e-05	0.000114	CcSEcCtD
Rivaroxaban—Fatigue—Prednisone—hematologic cancer	2.86e-05	0.000114	CcSEcCtD
Rivaroxaban—Headache—Prednisolone—hematologic cancer	2.86e-05	0.000114	CcSEcCtD
Rivaroxaban—Discomfort—Methotrexate—hematologic cancer	2.86e-05	0.000114	CcSEcCtD
Rivaroxaban—Syncope—Epirubicin—hematologic cancer	2.85e-05	0.000113	CcSEcCtD
Rivaroxaban—Back pain—Doxorubicin—hematologic cancer	2.85e-05	0.000113	CcSEcCtD
Rivaroxaban—Constipation—Prednisone—hematologic cancer	2.84e-05	0.000113	CcSEcCtD
Rivaroxaban—Muscle spasms—Doxorubicin—hematologic cancer	2.83e-05	0.000113	CcSEcCtD
Rivaroxaban—Loss of consciousness—Epirubicin—hematologic cancer	2.8e-05	0.000111	CcSEcCtD
Rivaroxaban—Dizziness—Triamcinolone—hematologic cancer	2.78e-05	0.00011	CcSEcCtD
Rivaroxaban—Anaphylactic shock—Methotrexate—hematologic cancer	2.77e-05	0.00011	CcSEcCtD
Rivaroxaban—Infection—Methotrexate—hematologic cancer	2.76e-05	0.00011	CcSEcCtD
Rivaroxaban—Nausea—Etoposide—hematologic cancer	2.75e-05	0.000109	CcSEcCtD
Rivaroxaban—Feeling abnormal—Prednisone—hematologic cancer	2.74e-05	0.000109	CcSEcCtD
Rivaroxaban—Asthenia—Betamethasone—hematologic cancer	2.74e-05	0.000109	CcSEcCtD
Rivaroxaban—Asthenia—Dexamethasone—hematologic cancer	2.74e-05	0.000109	CcSEcCtD
Rivaroxaban—Ill-defined disorder—Doxorubicin—hematologic cancer	2.73e-05	0.000109	CcSEcCtD
Rivaroxaban—Nervous system disorder—Methotrexate—hematologic cancer	2.72e-05	0.000108	CcSEcCtD
Rivaroxaban—Anaemia—Doxorubicin—hematologic cancer	2.72e-05	0.000108	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Prednisone—hematologic cancer	2.71e-05	0.000108	CcSEcCtD
Rivaroxaban—Nausea—Prednisolone—hematologic cancer	2.71e-05	0.000108	CcSEcCtD
Rivaroxaban—Chest pain—Epirubicin—hematologic cancer	2.71e-05	0.000108	CcSEcCtD
Rivaroxaban—Pruritus—Betamethasone—hematologic cancer	2.7e-05	0.000107	CcSEcCtD
Rivaroxaban—Pruritus—Dexamethasone—hematologic cancer	2.7e-05	0.000107	CcSEcCtD
Rivaroxaban—Skin disorder—Methotrexate—hematologic cancer	2.69e-05	0.000107	CcSEcCtD
Rivaroxaban—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	2.69e-05	0.000107	CcSEcCtD
Rivaroxaban—Discomfort—Epirubicin—hematologic cancer	2.68e-05	0.000106	CcSEcCtD
Rivaroxaban—Vomiting—Triamcinolone—hematologic cancer	2.67e-05	0.000106	CcSEcCtD
Rivaroxaban—Malaise—Doxorubicin—hematologic cancer	2.65e-05	0.000106	CcSEcCtD
Rivaroxaban—Rash—Triamcinolone—hematologic cancer	2.65e-05	0.000105	CcSEcCtD
Rivaroxaban—Dry mouth—Epirubicin—hematologic cancer	2.65e-05	0.000105	CcSEcCtD
Rivaroxaban—Dermatitis—Triamcinolone—hematologic cancer	2.65e-05	0.000105	CcSEcCtD
Rivaroxaban—Syncope—Doxorubicin—hematologic cancer	2.64e-05	0.000105	CcSEcCtD
Rivaroxaban—Urticaria—Prednisone—hematologic cancer	2.64e-05	0.000105	CcSEcCtD
Rivaroxaban—Headache—Triamcinolone—hematologic cancer	2.63e-05	0.000105	CcSEcCtD
Rivaroxaban—Abdominal pain—Prednisone—hematologic cancer	2.62e-05	0.000104	CcSEcCtD
Rivaroxaban—Diarrhoea—Dexamethasone—hematologic cancer	2.61e-05	0.000104	CcSEcCtD
Rivaroxaban—Diarrhoea—Betamethasone—hematologic cancer	2.61e-05	0.000104	CcSEcCtD
Rivaroxaban—Anaphylactic shock—Epirubicin—hematologic cancer	2.6e-05	0.000103	CcSEcCtD
Rivaroxaban—Oedema—Epirubicin—hematologic cancer	2.6e-05	0.000103	CcSEcCtD
Rivaroxaban—Hypotension—Methotrexate—hematologic cancer	2.59e-05	0.000103	CcSEcCtD
Rivaroxaban—Loss of consciousness—Doxorubicin—hematologic cancer	2.59e-05	0.000103	CcSEcCtD
Rivaroxaban—Infection—Epirubicin—hematologic cancer	2.58e-05	0.000103	CcSEcCtD
Rivaroxaban—Shock—Epirubicin—hematologic cancer	2.55e-05	0.000102	CcSEcCtD
Rivaroxaban—Nervous system disorder—Epirubicin—hematologic cancer	2.55e-05	0.000101	CcSEcCtD
Rivaroxaban—Tachycardia—Epirubicin—hematologic cancer	2.53e-05	0.000101	CcSEcCtD
Rivaroxaban—Skin disorder—Epirubicin—hematologic cancer	2.52e-05	0.0001	CcSEcCtD
Rivaroxaban—Dizziness—Betamethasone—hematologic cancer	2.52e-05	0.0001	CcSEcCtD
Rivaroxaban—Dizziness—Dexamethasone—hematologic cancer	2.52e-05	0.0001	CcSEcCtD
Rivaroxaban—CYP3A5—Metabolism—B3GAT1—hematologic cancer	2.52e-05	0.000406	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—DCK—hematologic cancer	2.52e-05	0.000406	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—ASNS—hematologic cancer	2.52e-05	0.000406	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—PDGFRA—hematologic cancer	2.51e-05	0.000404	CbGpPWpGaD
Rivaroxaban—Chest pain—Doxorubicin—hematologic cancer	2.51e-05	9.97e-05	CcSEcCtD
Rivaroxaban—Nausea—Triamcinolone—hematologic cancer	2.5e-05	9.93e-05	CcSEcCtD
Rivaroxaban—F10—Hemostasis—VEGFA—hematologic cancer	2.49e-05	0.000402	CbGpPWpGaD
Rivaroxaban—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	2.49e-05	9.9e-05	CcSEcCtD
Rivaroxaban—Discomfort—Doxorubicin—hematologic cancer	2.48e-05	9.85e-05	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	2.47e-05	0.000399	CbGpPWpGaD
Rivaroxaban—Dyspnoea—Methotrexate—hematologic cancer	2.47e-05	9.84e-05	CcSEcCtD
Rivaroxaban—F10—Hemostasis—NRAS—hematologic cancer	2.46e-05	0.000397	CbGpPWpGaD
Rivaroxaban—Dry mouth—Doxorubicin—hematologic cancer	2.45e-05	9.75e-05	CcSEcCtD
Rivaroxaban—Hypersensitivity—Prednisone—hematologic cancer	2.45e-05	9.73e-05	CcSEcCtD
Rivaroxaban—Dyspepsia—Methotrexate—hematologic cancer	2.44e-05	9.71e-05	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism—GSTP1—hematologic cancer	2.44e-05	0.000393	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—FASLG—hematologic cancer	2.44e-05	0.000393	CbGpPWpGaD
Rivaroxaban—Hypotension—Epirubicin—hematologic cancer	2.43e-05	9.65e-05	CcSEcCtD
Rivaroxaban—Vomiting—Dexamethasone—hematologic cancer	2.42e-05	9.64e-05	CcSEcCtD
Rivaroxaban—Vomiting—Betamethasone—hematologic cancer	2.42e-05	9.64e-05	CcSEcCtD
Rivaroxaban—Rash—Betamethasone—hematologic cancer	2.4e-05	9.56e-05	CcSEcCtD
Rivaroxaban—Rash—Dexamethasone—hematologic cancer	2.4e-05	9.56e-05	CcSEcCtD
Rivaroxaban—Oedema—Doxorubicin—hematologic cancer	2.4e-05	9.56e-05	CcSEcCtD
Rivaroxaban—Anaphylactic shock—Doxorubicin—hematologic cancer	2.4e-05	9.56e-05	CcSEcCtD
Rivaroxaban—Dermatitis—Betamethasone—hematologic cancer	2.4e-05	9.55e-05	CcSEcCtD
Rivaroxaban—Dermatitis—Dexamethasone—hematologic cancer	2.4e-05	9.55e-05	CcSEcCtD
Rivaroxaban—ABCB1—Transmembrane transport of small molecules—TUBB2A—hematologic cancer	2.4e-05	0.000387	CbGpPWpGaD
Rivaroxaban—Gastrointestinal disorder—Methotrexate—hematologic cancer	2.4e-05	9.53e-05	CcSEcCtD
Rivaroxaban—Fatigue—Methotrexate—hematologic cancer	2.39e-05	9.51e-05	CcSEcCtD
Rivaroxaban—Headache—Dexamethasone—hematologic cancer	2.39e-05	9.5e-05	CcSEcCtD
Rivaroxaban—Headache—Betamethasone—hematologic cancer	2.39e-05	9.5e-05	CcSEcCtD
Rivaroxaban—CYP3A5—Metabolism—HDC—hematologic cancer	2.39e-05	0.000385	CbGpPWpGaD
Rivaroxaban—Infection—Doxorubicin—hematologic cancer	2.39e-05	9.49e-05	CcSEcCtD
Rivaroxaban—Asthenia—Prednisone—hematologic cancer	2.38e-05	9.47e-05	CcSEcCtD
Rivaroxaban—ABCB1—Metabolism—FTCD—hematologic cancer	2.38e-05	0.000383	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—GMPS—hematologic cancer	2.38e-05	0.000383	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—PHYH—hematologic cancer	2.38e-05	0.000383	CbGpPWpGaD
Rivaroxaban—Pain—Methotrexate—hematologic cancer	2.37e-05	9.44e-05	CcSEcCtD
Rivaroxaban—Shock—Doxorubicin—hematologic cancer	2.36e-05	9.4e-05	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	2.36e-05	0.00038	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—MAPK3—hematologic cancer	2.36e-05	0.00038	CbGpPWpGaD
Rivaroxaban—ABCB1—Allograft Rejection—VEGFA—hematologic cancer	2.36e-05	0.00038	CbGpPWpGaD
Rivaroxaban—Nervous system disorder—Doxorubicin—hematologic cancer	2.36e-05	9.37e-05	CcSEcCtD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—hematologic cancer	2.35e-05	0.000379	CbGpPWpGaD
Rivaroxaban—Pruritus—Prednisone—hematologic cancer	2.35e-05	9.34e-05	CcSEcCtD
Rivaroxaban—Tachycardia—Doxorubicin—hematologic cancer	2.34e-05	9.33e-05	CcSEcCtD
Rivaroxaban—Skin disorder—Doxorubicin—hematologic cancer	2.33e-05	9.28e-05	CcSEcCtD
Rivaroxaban—Dyspnoea—Epirubicin—hematologic cancer	2.31e-05	9.21e-05	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism—ABCB1—hematologic cancer	2.31e-05	0.000372	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—TGFB1—hematologic cancer	2.29e-05	0.000369	CbGpPWpGaD
Rivaroxaban—Feeling abnormal—Methotrexate—hematologic cancer	2.29e-05	9.09e-05	CcSEcCtD
Rivaroxaban—Dyspepsia—Epirubicin—hematologic cancer	2.29e-05	9.09e-05	CcSEcCtD
Rivaroxaban—Diarrhoea—Prednisone—hematologic cancer	2.27e-05	9.03e-05	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Methotrexate—hematologic cancer	2.27e-05	9.02e-05	CcSEcCtD
Rivaroxaban—Nausea—Dexamethasone—hematologic cancer	2.26e-05	9.01e-05	CcSEcCtD
Rivaroxaban—Nausea—Betamethasone—hematologic cancer	2.26e-05	9.01e-05	CcSEcCtD
Rivaroxaban—Hypotension—Doxorubicin—hematologic cancer	2.24e-05	8.93e-05	CcSEcCtD
Rivaroxaban—Gastrointestinal disorder—Epirubicin—hematologic cancer	2.24e-05	8.92e-05	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism—NCOR1—hematologic cancer	2.24e-05	0.000361	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—GSTM1—hematologic cancer	2.24e-05	0.000361	CbGpPWpGaD
Rivaroxaban—Fatigue—Epirubicin—hematologic cancer	2.24e-05	8.9e-05	CcSEcCtD
Rivaroxaban—Pain—Epirubicin—hematologic cancer	2.22e-05	8.83e-05	CcSEcCtD
Rivaroxaban—Constipation—Epirubicin—hematologic cancer	2.22e-05	8.83e-05	CcSEcCtD
Rivaroxaban—Urticaria—Methotrexate—hematologic cancer	2.2e-05	8.77e-05	CcSEcCtD
Rivaroxaban—Dizziness—Prednisone—hematologic cancer	2.2e-05	8.73e-05	CcSEcCtD
Rivaroxaban—Abdominal pain—Methotrexate—hematologic cancer	2.19e-05	8.72e-05	CcSEcCtD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—CDK2—hematologic cancer	2.19e-05	0.000352	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—CDA—hematologic cancer	2.18e-05	0.000352	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—SMPD3—hematologic cancer	2.17e-05	0.00035	CbGpPWpGaD
Rivaroxaban—ABCB1—Allograft Rejection—TGFB1—hematologic cancer	2.17e-05	0.000349	CbGpPWpGaD
Rivaroxaban—Dyspnoea—Doxorubicin—hematologic cancer	2.14e-05	8.52e-05	CcSEcCtD
Rivaroxaban—Feeling abnormal—Epirubicin—hematologic cancer	2.14e-05	8.51e-05	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Epirubicin—hematologic cancer	2.12e-05	8.44e-05	CcSEcCtD
Rivaroxaban—F10—Hemostasis—KRAS—hematologic cancer	2.12e-05	0.000342	CbGpPWpGaD
Rivaroxaban—Dyspepsia—Doxorubicin—hematologic cancer	2.11e-05	8.41e-05	CcSEcCtD
Rivaroxaban—Vomiting—Prednisone—hematologic cancer	2.11e-05	8.4e-05	CcSEcCtD
Rivaroxaban—ABCB1—Transmembrane transport of small molecules—ABCC3—hematologic cancer	2.11e-05	0.00034	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—PC—hematologic cancer	2.1e-05	0.000339	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK14—hematologic cancer	2.1e-05	0.000338	CbGpPWpGaD
Rivaroxaban—Rash—Prednisone—hematologic cancer	2.09e-05	8.33e-05	CcSEcCtD
Rivaroxaban—Dermatitis—Prednisone—hematologic cancer	2.09e-05	8.32e-05	CcSEcCtD
Rivaroxaban—Headache—Prednisone—hematologic cancer	2.08e-05	8.27e-05	CcSEcCtD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—ATM—hematologic cancer	2.08e-05	0.000335	CbGpPWpGaD
Rivaroxaban—Gastrointestinal disorder—Doxorubicin—hematologic cancer	2.07e-05	8.25e-05	CcSEcCtD
Rivaroxaban—Fatigue—Doxorubicin—hematologic cancer	2.07e-05	8.24e-05	CcSEcCtD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—hematologic cancer	2.07e-05	0.000333	CbGpPWpGaD
Rivaroxaban—Urticaria—Epirubicin—hematologic cancer	2.06e-05	8.2e-05	CcSEcCtD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—hematologic cancer	2.06e-05	0.000332	CbGpPWpGaD
Rivaroxaban—Pain—Doxorubicin—hematologic cancer	2.05e-05	8.17e-05	CcSEcCtD
Rivaroxaban—Constipation—Doxorubicin—hematologic cancer	2.05e-05	8.17e-05	CcSEcCtD
Rivaroxaban—Abdominal pain—Epirubicin—hematologic cancer	2.05e-05	8.16e-05	CcSEcCtD
Rivaroxaban—Hypersensitivity—Methotrexate—hematologic cancer	2.04e-05	8.13e-05	CcSEcCtD
Rivaroxaban—CYP3A5—Metabolism—SLC35B2—hematologic cancer	2.03e-05	0.000327	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—GBA—hematologic cancer	2.03e-05	0.000327	CbGpPWpGaD
Rivaroxaban—ABCB1—Allograft Rejection—TNF—hematologic cancer	2.02e-05	0.000326	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—hematologic cancer	2.01e-05	0.000324	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—BAD—hematologic cancer	2.01e-05	0.000324	CbGpPWpGaD
Rivaroxaban—Asthenia—Methotrexate—hematologic cancer	1.99e-05	7.92e-05	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism—MTHFR—hematologic cancer	1.98e-05	0.000319	CbGpPWpGaD
Rivaroxaban—Feeling abnormal—Doxorubicin—hematologic cancer	1.98e-05	7.87e-05	CcSEcCtD
Rivaroxaban—Nausea—Prednisone—hematologic cancer	1.97e-05	7.84e-05	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Doxorubicin—hematologic cancer	1.96e-05	7.81e-05	CcSEcCtD
Rivaroxaban—Pruritus—Methotrexate—hematologic cancer	1.96e-05	7.81e-05	CcSEcCtD
Rivaroxaban—F10—Hemostasis—PIK3CA—hematologic cancer	1.95e-05	0.000314	CbGpPWpGaD
Rivaroxaban—ABCB1—Transmembrane transport of small molecules—SLC22A1—hematologic cancer	1.93e-05	0.000311	CbGpPWpGaD
Rivaroxaban—Hypersensitivity—Epirubicin—hematologic cancer	1.91e-05	7.61e-05	CcSEcCtD
Rivaroxaban—CYP3A4—Biological oxidations—GSTP1—hematologic cancer	1.91e-05	0.000308	CbGpPWpGaD
Rivaroxaban—Urticaria—Doxorubicin—hematologic cancer	1.91e-05	7.59e-05	CcSEcCtD
Rivaroxaban—ABCB1—Metabolism—ASNS—hematologic cancer	1.9e-05	0.000306	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—DCK—hematologic cancer	1.9e-05	0.000306	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—B3GAT1—hematologic cancer	1.9e-05	0.000306	CbGpPWpGaD
Rivaroxaban—Abdominal pain—Doxorubicin—hematologic cancer	1.9e-05	7.55e-05	CcSEcCtD
Rivaroxaban—Diarrhoea—Methotrexate—hematologic cancer	1.9e-05	7.55e-05	CcSEcCtD
Rivaroxaban—CYP3A4—Metapathway biotransformation—GSTP1—hematologic cancer	1.88e-05	0.000304	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—TP53—hematologic cancer	1.88e-05	0.000304	CbGpPWpGaD
Rivaroxaban—Asthenia—Epirubicin—hematologic cancer	1.86e-05	7.41e-05	CcSEcCtD
Rivaroxaban—CYP3A5—Metabolism—MTAP—hematologic cancer	1.86e-05	0.000299	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—CREB1—hematologic cancer	1.85e-05	0.000299	CbGpPWpGaD
Rivaroxaban—Pruritus—Epirubicin—hematologic cancer	1.84e-05	7.31e-05	CcSEcCtD
Rivaroxaban—Dizziness—Methotrexate—hematologic cancer	1.83e-05	7.3e-05	CcSEcCtD
Rivaroxaban—ABCB1—Transmembrane transport of small molecules—NUP98—hematologic cancer	1.82e-05	0.000293	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—hematologic cancer	1.81e-05	0.000292	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—CREBBP—hematologic cancer	1.8e-05	0.000291	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—HRAS—hematologic cancer	1.8e-05	0.00029	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—HDC—hematologic cancer	1.8e-05	0.00029	CbGpPWpGaD
Rivaroxaban—Diarrhoea—Epirubicin—hematologic cancer	1.78e-05	7.07e-05	CcSEcCtD
Rivaroxaban—Hypersensitivity—Doxorubicin—hematologic cancer	1.77e-05	7.04e-05	CcSEcCtD
Rivaroxaban—ABCB1—Transmembrane transport of small molecules—ADCY7—hematologic cancer	1.77e-05	0.000285	CbGpPWpGaD
Rivaroxaban—Vomiting—Methotrexate—hematologic cancer	1.76e-05	7.02e-05	CcSEcCtD
Rivaroxaban—CYP3A4—Biological oxidations—GSTM1—hematologic cancer	1.76e-05	0.000283	CbGpPWpGaD
Rivaroxaban—ABCB1—Transmembrane transport of small molecules—NUP214—hematologic cancer	1.75e-05	0.000283	CbGpPWpGaD
Rivaroxaban—Rash—Methotrexate—hematologic cancer	1.75e-05	6.96e-05	CcSEcCtD
Rivaroxaban—Dermatitis—Methotrexate—hematologic cancer	1.75e-05	6.95e-05	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.75e-05	0.000281	CbGpPWpGaD
Rivaroxaban—Headache—Methotrexate—hematologic cancer	1.74e-05	6.91e-05	CcSEcCtD
Rivaroxaban—ABCB1—HIF-1-alpha transcription factor network—AKT1—hematologic cancer	1.74e-05	0.00028	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metapathway biotransformation—GSTM1—hematologic cancer	1.73e-05	0.000279	CbGpPWpGaD
Rivaroxaban—Asthenia—Doxorubicin—hematologic cancer	1.72e-05	6.86e-05	CcSEcCtD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—MAP2K1—hematologic cancer	1.72e-05	0.000278	CbGpPWpGaD
Rivaroxaban—ABCB1—Transmembrane transport of small molecules—ABCG2—hematologic cancer	1.72e-05	0.000277	CbGpPWpGaD
Rivaroxaban—Dizziness—Epirubicin—hematologic cancer	1.72e-05	6.83e-05	CcSEcCtD
Rivaroxaban—Pruritus—Doxorubicin—hematologic cancer	1.7e-05	6.76e-05	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism—PIK3CG—hematologic cancer	1.66e-05	0.000268	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—FHL2—hematologic cancer	1.65e-05	0.000267	CbGpPWpGaD
Rivaroxaban—Vomiting—Epirubicin—hematologic cancer	1.65e-05	6.57e-05	CcSEcCtD
Rivaroxaban—Nausea—Methotrexate—hematologic cancer	1.65e-05	6.55e-05	CcSEcCtD
Rivaroxaban—ABCB1—Metabolism—CDA—hematologic cancer	1.65e-05	0.000265	CbGpPWpGaD
Rivaroxaban—Diarrhoea—Doxorubicin—hematologic cancer	1.64e-05	6.54e-05	CcSEcCtD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—FGF2—hematologic cancer	1.64e-05	0.000264	CbGpPWpGaD
Rivaroxaban—Rash—Epirubicin—hematologic cancer	1.64e-05	6.51e-05	CcSEcCtD
Rivaroxaban—Dermatitis—Epirubicin—hematologic cancer	1.64e-05	6.51e-05	CcSEcCtD
Rivaroxaban—Headache—Epirubicin—hematologic cancer	1.63e-05	6.47e-05	CcSEcCtD
Rivaroxaban—CYP3A5—Metabolism—AGRN—hematologic cancer	1.62e-05	0.000261	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—AKT1—hematologic cancer	1.59e-05	0.000256	CbGpPWpGaD
Rivaroxaban—Dizziness—Doxorubicin—hematologic cancer	1.59e-05	6.32e-05	CcSEcCtD
Rivaroxaban—ABCB1—Metabolism—PC—hematologic cancer	1.59e-05	0.000256	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—hematologic cancer	1.56e-05	0.000251	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—CREBBP—hematologic cancer	1.54e-05	0.000249	CbGpPWpGaD
Rivaroxaban—Nausea—Epirubicin—hematologic cancer	1.54e-05	6.13e-05	CcSEcCtD
Rivaroxaban—CYP3A5—Metabolism—HMMR—hematologic cancer	1.54e-05	0.000248	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—IDH2—hematologic cancer	1.54e-05	0.000248	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—hematologic cancer	1.53e-05	0.000247	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—GBA—hematologic cancer	1.53e-05	0.000247	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—SLC35B2—hematologic cancer	1.53e-05	0.000247	CbGpPWpGaD
Rivaroxaban—ABCB1—Transmembrane transport of small molecules—TFRC—hematologic cancer	1.53e-05	0.000247	CbGpPWpGaD
Rivaroxaban—Vomiting—Doxorubicin—hematologic cancer	1.53e-05	6.08e-05	CcSEcCtD
Rivaroxaban—Rash—Doxorubicin—hematologic cancer	1.51e-05	6.02e-05	CcSEcCtD
Rivaroxaban—Dermatitis—Doxorubicin—hematologic cancer	1.51e-05	6.02e-05	CcSEcCtD
Rivaroxaban—Headache—Doxorubicin—hematologic cancer	1.51e-05	5.99e-05	CcSEcCtD
Rivaroxaban—CYP3A4—Metabolism—FTCD—hematologic cancer	1.46e-05	0.000236	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—GMPS—hematologic cancer	1.46e-05	0.000236	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—PHYH—hematologic cancer	1.46e-05	0.000236	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—PIK3CD—hematologic cancer	1.46e-05	0.000236	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—ARNTL—hematologic cancer	1.45e-05	0.000233	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—ALB—hematologic cancer	1.44e-05	0.000233	CbGpPWpGaD
Rivaroxaban—Nausea—Doxorubicin—hematologic cancer	1.43e-05	5.68e-05	CcSEcCtD
Rivaroxaban—CYP3A5—Metabolism—CA9—hematologic cancer	1.41e-05	0.000227	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—ACP5—hematologic cancer	1.41e-05	0.000227	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—MTAP—hematologic cancer	1.4e-05	0.000226	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—hematologic cancer	1.4e-05	0.000226	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—NCOR2—hematologic cancer	1.39e-05	0.000224	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—PIK3R1—hematologic cancer	1.38e-05	0.000223	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—hematologic cancer	1.37e-05	0.000221	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—SMPD3—hematologic cancer	1.34e-05	0.000216	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—hematologic cancer	1.34e-05	0.000215	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—hematologic cancer	1.33e-05	0.000215	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—IDH1—hematologic cancer	1.32e-05	0.000213	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—TXN—hematologic cancer	1.31e-05	0.000211	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—GSTO1—hematologic cancer	1.31e-05	0.000211	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—ABCC3—hematologic cancer	1.31e-05	0.000211	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—hematologic cancer	1.29e-05	0.000208	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—hematologic cancer	1.29e-05	0.000208	CbGpPWpGaD
Rivaroxaban—ABCB1—Transmembrane transport of small molecules—CYCS—hematologic cancer	1.28e-05	0.000207	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—SPHK1—hematologic cancer	1.28e-05	0.000206	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—PIK3CB—hematologic cancer	1.28e-05	0.000205	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK8—hematologic cancer	1.26e-05	0.000203	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—FHL2—hematologic cancer	1.25e-05	0.000201	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—UGT1A1—hematologic cancer	1.23e-05	0.000198	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—hematologic cancer	1.23e-05	0.000198	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—AGRN—hematologic cancer	1.22e-05	0.000197	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—SLC22A1—hematologic cancer	1.2e-05	0.000193	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—CRABP1—hematologic cancer	1.2e-05	0.000193	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—hematologic cancer	1.2e-05	0.000193	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—DCK—hematologic cancer	1.17e-05	0.000189	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—B3GAT1—hematologic cancer	1.17e-05	0.000189	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—ASNS—hematologic cancer	1.17e-05	0.000189	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—ALOX5—hematologic cancer	1.17e-05	0.000188	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—hematologic cancer	1.16e-05	0.000188	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—HMMR—hematologic cancer	1.16e-05	0.000187	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—IDH2—hematologic cancer	1.16e-05	0.000187	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—NUP98—hematologic cancer	1.13e-05	0.000182	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—HDC—hematologic cancer	1.11e-05	0.000179	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—PTEN—hematologic cancer	1.1e-05	0.000178	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—hematologic cancer	1.1e-05	0.000177	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—ADCY7—hematologic cancer	1.1e-05	0.000177	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—NCOA3—hematologic cancer	1.1e-05	0.000177	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—ARNTL—hematologic cancer	1.09e-05	0.000176	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—NUP214—hematologic cancer	1.09e-05	0.000175	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—hematologic cancer	1.07e-05	0.000173	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—hematologic cancer	1.07e-05	0.000172	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—MTR—hematologic cancer	1.07e-05	0.000172	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—ABCG2—hematologic cancer	1.07e-05	0.000172	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—CA9—hematologic cancer	1.06e-05	0.000171	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—ACP5—hematologic cancer	1.06e-05	0.000171	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—EP300—hematologic cancer	1.05e-05	0.000169	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—NCOR2—hematologic cancer	1.05e-05	0.000169	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—ENO2—hematologic cancer	1.05e-05	0.000168	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—CDA—hematologic cancer	1.02e-05	0.000164	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—GSTT1—hematologic cancer	1.01e-05	0.000163	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—IDH1—hematologic cancer	9.98e-06	0.000161	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—hematologic cancer	9.98e-06	0.000161	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—SDC1—hematologic cancer	9.91e-06	0.00016	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—hematologic cancer	9.9e-06	0.000159	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—GSTO1—hematologic cancer	9.87e-06	0.000159	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—ABCC3—hematologic cancer	9.87e-06	0.000159	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—TXN—hematologic cancer	9.87e-06	0.000159	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—PC—hematologic cancer	9.77e-06	0.000157	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—SPHK1—hematologic cancer	9.66e-06	0.000156	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—GBA—hematologic cancer	9.44e-06	0.000152	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—SLC35B2—hematologic cancer	9.44e-06	0.000152	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—UGT1A1—hematologic cancer	9.28e-06	0.00015	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—hematologic cancer	9.09e-06	0.000146	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—SLC22A1—hematologic cancer	9.03e-06	0.000145	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—CRABP1—hematologic cancer	9.03e-06	0.000145	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—ALOX5—hematologic cancer	8.8e-06	0.000142	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—hematologic cancer	8.8e-06	0.000142	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—MTAP—hematologic cancer	8.63e-06	0.000139	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—NUP98—hematologic cancer	8.52e-06	0.000137	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—CD44—hematologic cancer	8.43e-06	0.000136	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—NQO1—hematologic cancer	8.43e-06	0.000136	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—ADCY7—hematologic cancer	8.27e-06	0.000133	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—NCOA3—hematologic cancer	8.27e-06	0.000133	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—NUP214—hematologic cancer	8.21e-06	0.000132	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—ABCG2—hematologic cancer	8.05e-06	0.00013	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—MTR—hematologic cancer	8.05e-06	0.00013	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—CYCS—hematologic cancer	7.98e-06	0.000128	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—HSP90AA1—hematologic cancer	7.92e-06	0.000128	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—ENO2—hematologic cancer	7.89e-06	0.000127	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—PIK3CA—hematologic cancer	7.77e-06	0.000125	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—FHL2—hematologic cancer	7.69e-06	0.000124	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—GSTT1—hematologic cancer	7.65e-06	0.000123	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—AGRN—hematologic cancer	7.54e-06	0.000122	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—SDC1—hematologic cancer	7.48e-06	0.000121	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—hematologic cancer	7.43e-06	0.00012	CbGpPWpGaD
Rivaroxaban—ABCB1—Transmembrane transport of small molecules—CREBBP—hematologic cancer	7.17e-06	0.000115	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—HMMR—hematologic cancer	7.15e-06	0.000115	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—IDH2—hematologic cancer	7.15e-06	0.000115	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—GSTP1—hematologic cancer	7.03e-06	0.000113	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—ARNTL—hematologic cancer	6.72e-06	0.000108	CbGpPWpGaD
Rivaroxaban—ABCB1—Transmembrane transport of small molecules—ALB—hematologic cancer	6.71e-06	0.000108	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—ABCB1—hematologic cancer	6.65e-06	0.000107	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—CA9—hematologic cancer	6.54e-06	0.000105	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—ACP5—hematologic cancer	6.54e-06	0.000105	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—NCOR1—hematologic cancer	6.46e-06	0.000104	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—GSTM1—hematologic cancer	6.46e-06	0.000104	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—NCOR2—hematologic cancer	6.46e-06	0.000104	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—NQO1—hematologic cancer	6.36e-06	0.000102	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—CD44—hematologic cancer	6.36e-06	0.000102	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—AKT1—hematologic cancer	6.35e-06	0.000102	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—IDH1—hematologic cancer	6.15e-06	9.91e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—GSTO1—hematologic cancer	6.08e-06	9.8e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—TXN—hematologic cancer	6.08e-06	9.8e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—ABCC3—hematologic cancer	6.08e-06	9.8e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—CYCS—hematologic cancer	6.02e-06	9.7e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—HSP90AA1—hematologic cancer	5.98e-06	9.63e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—SPHK1—hematologic cancer	5.95e-06	9.59e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—UGT1A1—hematologic cancer	5.72e-06	9.21e-05	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—MTHFR—hematologic cancer	5.71e-06	9.2e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—CRABP1—hematologic cancer	5.56e-06	8.96e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—SLC22A1—hematologic cancer	5.56e-06	8.96e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—ALOX5—hematologic cancer	5.42e-06	8.73e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—GSTP1—hematologic cancer	5.3e-06	8.55e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—NUP98—hematologic cancer	5.25e-06	8.46e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—NCOA3—hematologic cancer	5.1e-06	8.21e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—ADCY7—hematologic cancer	5.1e-06	8.21e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—NUP214—hematologic cancer	5.06e-06	8.15e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—ABCG2—hematologic cancer	4.96e-06	7.99e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—MTR—hematologic cancer	4.96e-06	7.99e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—NCOR1—hematologic cancer	4.87e-06	7.85e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—GSTM1—hematologic cancer	4.87e-06	7.85e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—ENO2—hematologic cancer	4.86e-06	7.83e-05	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—PIK3CG—hematologic cancer	4.8e-06	7.73e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—GSTT1—hematologic cancer	4.72e-06	7.6e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—SDC1—hematologic cancer	4.61e-06	7.43e-05	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—CREBBP—hematologic cancer	4.45e-06	7.17e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—MTHFR—hematologic cancer	4.31e-06	6.94e-05	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—PIK3CD—hematologic cancer	4.22e-06	6.79e-05	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—ALB—hematologic cancer	4.16e-06	6.71e-05	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—PIK3R1—hematologic cancer	3.98e-06	6.42e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—CD44—hematologic cancer	3.92e-06	6.31e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—NQO1—hematologic cancer	3.92e-06	6.31e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—CYCS—hematologic cancer	3.71e-06	5.97e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	3.68e-06	5.94e-05	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—PIK3CB—hematologic cancer	3.68e-06	5.92e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—PIK3CG—hematologic cancer	3.62e-06	5.83e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—CREBBP—hematologic cancer	3.36e-06	5.41e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—GSTP1—hematologic cancer	3.27e-06	5.27e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—PIK3CD—hematologic cancer	3.18e-06	5.13e-05	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—PTEN—hematologic cancer	3.18e-06	5.12e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—ALB—hematologic cancer	3.14e-06	5.06e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—ABCB1—hematologic cancer	3.09e-06	4.98e-05	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—EP300—hematologic cancer	3.03e-06	4.88e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—PIK3R1—hematologic cancer	3e-06	4.84e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—GSTM1—hematologic cancer	3e-06	4.84e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—NCOR1—hematologic cancer	3e-06	4.84e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—PIK3CB—hematologic cancer	2.77e-06	4.47e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—MTHFR—hematologic cancer	2.65e-06	4.28e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—PTEN—hematologic cancer	2.4e-06	3.86e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—EP300—hematologic cancer	2.29e-06	3.68e-05	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—PIK3CA—hematologic cancer	2.24e-06	3.61e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—PIK3CG—hematologic cancer	2.23e-06	3.59e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—CREBBP—hematologic cancer	2.07e-06	3.33e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—PIK3CD—hematologic cancer	1.96e-06	3.16e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—ALB—hematologic cancer	1.94e-06	3.12e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—PIK3R1—hematologic cancer	1.85e-06	2.98e-05	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—AKT1—hematologic cancer	1.83e-06	2.95e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—PIK3CB—hematologic cancer	1.71e-06	2.75e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—PIK3CA—hematologic cancer	1.69e-06	2.72e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—PTEN—hematologic cancer	1.48e-06	2.38e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—EP300—hematologic cancer	1.41e-06	2.27e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—AKT1—hematologic cancer	1.38e-06	2.23e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—PIK3CA—hematologic cancer	1.04e-06	1.68e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—AKT1—hematologic cancer	8.51e-07	1.37e-05	CbGpPWpGaD
